The Rheumatology Drugs for COVID-19 Management: Which and When?

The Rheumatology Drugs for COVID-19 Management: Which and When?

Introduction: While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and...

Full description

Bibliographic Details
Main Authors: Fabiola Atzeni, Ignazio Francesco Masala, Javier Rodríguez-Carrio, Roberto Ríos-Garcés, Elisabetta Gerratana, Laura La Corte, Manuela Giallanza, Valeria Nucera, Agostino Riva, Gerard Espinosa, Ricard Cervera
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Journal of Clinical Medicine
Subjects:
pneumonia
COVID-19
SARS-CoV2
anti-IL-6 drugs
HCQ
Online Access:https://www.mdpi.com/2077-0383/10/4/783

Internet

https://www.mdpi.com/2077-0383/10/4/783

Similar Items